Sports and Athletic Performance Enhancing Supplements Sports and Athletic Performance Enhancing Supplements Sports and Athletic Performance Enhancing Supplements - shopping cart Sports and Athletic Performance Enhancing Supplements - account Sports and Athletic Performance Enhancing Supplements - checkout search for Sports and Athletic Performance Enhancing Supplements
Sports and Athletic Performance Enhancing Supplements
Home Shop Blog New Items About Mission Contact

Posts Tagged ‘muscle building product’

MASTER AMINO ACID PATTERN

Monday, November 17th, 2008

Master Amino Acid Pattern MAP  is a patented dietary protein supplement for rapid muscle building, which provides a unique pattern of 8 essential amino acids, in a highly purified, crystalline form. The product contains no additivesor doping substances and is considered one of the best muscle building supplements. Mucscle building products and informationare a mine field of bad information and worthless products sold by people that are more concerned with making a sale than giving you what you expect and want. MAAP is the right/exact combination of amino acids to feed the muscles, depending on the amount you take, will support, rebuild, and/or grow your muscles. Maximise your body production of protein.
Maximise your muscle strength and muscle volume.
Replace your body fat with muscles with the help of physical exercise.
Maximise your recovery after physical activity.
Strengthen and tighten your body tissues.

Use Master Amino Acid Pattern MAP to:

Click here to order your Master Amino Pattern.

Remarkable benefits:
Unique amino acid profile that provides 99% Net Nitrogen Utilization ‚ nearly all amino acids are used for body protein synthesis
Almost calorie-free (only 0.4 kcal per ten tablets) and provides you with the same amount of amino acids as about 350 g of meat, fish or poultry
Absorbed within 25 minutes – rapidly utilised without the aid of catabolic enzymes
Master Amino Acid Pattern MAP® is 100% essential amino acids extracted from dietary proteins
Free from fat, yeast, gluten, sugar, corn, wheat, and soya protein or dairy products

Product no. 1915
120 tablets

Contents
1 tablet contains the following amino acids: L-Leucine 0.20g, L-Valine 0.16 g, L-Isoleusine 0.15 g, L-Lysine 0.14 g, L-Phenylalanine 0.13 g, L-Methionine 0.07 g, L-Tryptophan 0.04 g

Recommended use
Take 3-5 tablets per day. The recommended daily dose should not be exceeded. This product is not intended to substitute a varied diet.

Storage
Keep in a cool, dry place.
Keep out of the reach of children.
Do not use if safety seal is missing or broken.

cGMP-manufactured
This product has been manufactured according to cGMP (current Good Manufacturing Practice), thereby guaranteeing the high quality of the manufacturing process. Quality Control is stringent at all stages of the process, from raw material to finished product. This product is well documented, and meets the requirements of the Swedish National Food Administration in terms of product safety, integrity and traceability.

Here is a study conducted on the power of the Master Amino Acid Pattern

To be published in ADVANCES IN THERAPY

©2001 International Nutrition Research Center 1

COMPARATIVE PHYSIOLOGICAL AND METABOLIC PARAMETERS RESULTS BETWEEN

TWO GROUPS OF ATHLETES WHILE PERFORMING TRACK AND FIELD RUNNING WITH

OR WITHOUT MASTER AMINO ACID PATTERN INTAKE

International Nutrition Research Center (USA)

M. Luca-Moretti

A. Grandi

E. Lucà

Sport Medicine Institute (Milan, Italy)

E. Mariani

G. Vender

E. Arrigotti

M. Ferrario

E. Rovelli

Introduction

The discovery of the Master Amino Acid Pattern (MAP) has been confirmed by a recent clinical

study (1,2). The results have shown that MAP‚amino acids profile provides a 99% Net

Nitrogen Utilization (NNU), therefore, originating only 1% of nitrogen catabolites (1,2). This

means that 99% of MAP‚ constituent amino acids act as precursors (building blocks) of body

protein synthesis, meanwhile only 1% follows the catabolic pathway, thus originating energy and

nitrogen catabolites (1,2). Due to these unique characteristics, we considered it interesting to

evaluate some physiological and metabolic parameters (3,4) among a group of athletes, while

taking MAP, as a nutritional supplement. The physiological parameters evaluated in the study

were correlated with the athletes‚ level of performance, using techniques typical in the sports

physiology (3,4).

Study Population

The study population included 20 healthy subjects, randomly chosen, 16 men and 4 women

They were randomly integrated, according to sex and number into two matched groups. Group

A integrated by 8 men and 2 women, with a mean age of 41.5 years (SD = 10.3; range 24-54),

mean height of 172.9 cm (SD = 7.1; range 163-183 cm), mean initial weight of 68.1 kg (SD =

10.4; range 50-78.5 kg). Group B integrated by 8 men and 2 women, with a mean age of 38.3

years (SD = 9.5; range 22-49), mean height of 173.2 cm (SD = 7.3; range 160-181 cm), mean

initial weight of 69.3 kg (SD = 12.1; range 46-81.5 kg) (Table I).

All of them gave their informed consent to participate in the study. The subjects were well

trained and well-nourished amateur or master athletes, who have been practicing track and field

running (400m) and (800-1,500m) at least during the previous three years. All of them were

members of the FIDAL (Federazione Italiana di Atletica Leggera).

Study Design and Methods

The study was carried out for a 28 day-period. During this period, group A subjects received, as

a sole nutritional supplement, 10g of MAP once a day during light training days (Tuesdays,

Thursdays and Saturdays). And 10 g of MAP twice a day, at breakfast, and 1 hour before

training during intense traisubjects did not received MAP at all, however they were taking other nutritional supplements.

The subjects‚ following hematochemical, anthropometrical, physiological and metabolic

parameters were determined at the beginning of the study (TO) and at the conclusion of the

study (T1) as follows:

a. Blood tests, such as urea, creatinine, hemochrome, sideremia, and ferritin. These tests were

performed by analyzing 15 ml. of blood taken from a peripheral vein.

b. Body composition tests, such as: body fat (%BF); lean tissue (LBW) (kg); Basal Metabolism

Rate (BMR) (Kcal/day); and lean tissue water (%BW). These tests were performed utilizing

the impendence methodology.

c. Isokinetic tests (to evaluate both knee extensor muscles) such as: PT60/sec (to recruit

indiscriminately all types of muscles fibers); PT300/sec (to test only the fast fibers type II);

AP, AE180/sec (measured in the first eighth of second of the effort); TW240/sec

(performing up to 20 repetitions); A/G60/sec; (A/G); PT300/PT 60 ratio; (+PT) (difference

between the PT of the right extensor muscles and the PT of the left extensor muscles); (+

TW) Difference between the TW of the right extensor muscles and the TW of the left

extensor muscles)(5,6,7), The previous isokinetic tests were performed with an ergometer

Cybex 340 Lumex Inc, Ronkonkoma,NY)

d. Lactic acid concentration cap tests. These tests were performed with an analyzer

Accusport‚ Mannhein- Boeringher, by analyzing a drop of capillary blood at two different

times: First time: After four minutes of running at a velocity target (VT) on a treadmill, in a

flat surface. Such velocity corresponded to the best performance per each athlete on the

3,000 meters. The VT was progressively reached through two steps of two minutes each.

The first step started with an initial velocity equal to 4km/h lower than VT and concluded at 2

km/h lower than VT. The second step started at 2 km/h lower than VT, and concluded, after

two minutes, reaching the VT. Second time: At the conclusion of the exhaustion test. The

exhaustion test was performed on a treadmill, in a flat surface. It started after two minutes of

the VT test conclusion with an initial velocity, equal to VT, which was progressively

increased by 1Km/h per each minute.

e. Cardio-Respiratory Tests. The respiratory tests were performed in conjunction with the

cap tests by attaching to each subject a mask of ‚ÄùVmax 29‚ (Sensor-Medics. Yorba

Linda-Ca-USA) to evaluate, during each breathing cycle, the following metabolic

parameters: VO2, VE, VCO2, and RQ). The hearth rate was evaluated with a ‚Polar,

cardiofrequencymeter.

Each athlete kept an individual record of his/her training, diet and general kinestesic status.

Study Results

The subjects’ anthropometric characteristics are shown in table I. The isokinetic test results are

shown in table II. The body composition results are shown in table III. The blood test results are

shown in table IV. The cap results related to the VT test and the exhaustion test such as

LaVT, LaVF, mM/L mean values are shown in table V. The VO2max, VE, VCO2, and VE/VO2

are shown also in table V.ning days (Mondays, Wednesday, Fridays and Sundays). Group B subjects did not received MAP at all, however they were taking other nutritional supplements.

The subjects‚ following hematochemical, anthropometrical, physiological and metabolic

parameters were determined at the beginning of the study (TO) and at the conclusion of the

study (T1) as follows:

a. Blood tests, such as urea, creatinine, hemochrome, sideremia, and ferritin. These tests were

performed by analyzing 15 ml. of blood taken from a peripheral vein.

b. Body composition tests, such as: body fat (%BF); lean tissue (LBW) (kg); Basal Metabolism

Rate (BMR) (Kcal/day); and lean tissue water (%BW). These tests were performed utilizing

the impendence methodology.

c. Isokinetic tests (to evaluate both knee extensor muscles) such as: PT60/sec (to recruit

indiscriminately all types of muscles fibers); PT300/sec (to test only the fast fibers type II);

AP, AE180/sec (measured in the first eighth of second of the effort); TW240/sec

(performing up to 20 repetitions); A/G60/sec; (A/G); PT300/PT 60 ratio; (+PT) (difference

between the PT of the right extensor muscles and the PT of the left extensor muscles); (+

TW) Difference between the TW of the right extensor muscles and the TW of the left

extensor muscles)(5,6,7), The previous isokinetic tests were performed with an ergometer

Cybex 340 Lumex Inc, Ronkonkoma,NY)

d. Lactic acid concentration cap tests. These tests were performed with an analyzer

‚ÄùAccusport‚ Mannhein- Boeringher, by analyzing a drop of capillary blood at two different

times: First time: After four minutes of running at a velocity target (VT) on a treadmill, in a

flat surface. Such velocity corresponded to the best performance per each athlete on the

3,000 meters. The VT was progressively reached through two steps of two minutes each.

The first step started with an initial velocity equal to 4km/h lower than VT and concluded at 2

km/h lower than VT. The second step started at 2 km/h lower than VT, and concluded, after

two minutes, reaching the VT. Second time: At the conclusion of the exhaustion test. The

exhaustion test was performed on a treadmill, in a flat surface. It started after two minutes of

the VT test conclusion with an initial velocity, equal to VT, which was progressively

increased by 1Km/h per each minute.

e. Cardio-Respiratory Tests. The respiratory tests were performed in conjunction with the

cap tests by attaching to each subject a mask of ‚Vmax 29‚Äù (Sensor-Medics. Yorba

Linda-Ca-USA) to evaluate, during each breathing cycle, the following metabolic

parameters: VO2, VE, VCO2, and RQ). The hearth rate was evaluated with a ‚Polar‚

cardiofrequencymeter.

Each athlete kept an individual record of his/her training, diet and general kinestesic status.

Study Results

The subjects‚ anthropometric characteristics are shown in table I. The isokinetic test results are

shown in table II. The body composition results are shown in table III. The blood test results are

shown in table IV. The cap results related to the VT test and the exhaustion test such as

LaVT, LaVF, mM/L mean values are shown in table V. The VO2max, VE, VCO2, and VE/VO2

are shown also in table V.

a. An increase of 1.4% (equivalent to 907g gain) in body lean tissue (%LBW) mean

percentage in group A subjects, in contrast with a decrease of -1.34% (equivalent to

437g loss) in body lean tissue mean percentage in group B subjects.

b. A decrease of – 0.34% (equivalent to 199g loss) in body fat (BF%) mean percentage in

group A subjects, in contrast with an increase of 12.7 % (equivalent to 1,334g gain) in

body fat tissue mean percentage in group B subjects.

c. An increase of 1.4% in the Basal Metabolism Rate (% BMR) mean percentage in group

A subjects, in contrast with a decrease of -1.6% in the BMR mean percentage in group B

subjects.

d. A 100% higher increase of the PT60 mean values in group A subjects, in comparison to

that obtained in group B subjects.

e. A 120 % higher increase of the PT300 mean values in group A subjects, in comparison

to that obtained in group B subjects.

f. A 17% higher mean increase of the AP300 in group A subjects, in comparison to that

obtained by group B subjects.

g. A 18% higher mean increase of the TW240 in group A subjects, in comparison to that

obtained by group B subjects.

h. An increase of 5.1% of the A/G60/sec (agonist/antagonist muscles) mean ratio in group

A subjects, in comparison to a decrease of -7.9 % in group B subjects, namely a

difference of 13% favorable to group A subjects. This means that group A subjects had

experienced a higher mean extensory muscles‚ increase, in comparison to their flexory

muscles.

i. A 157% higher increase of the PT300/PT60 ratio in group A subjects, in comparison to

that obtained by group B subjects.

j. A 106% higher decrease of cap at VT in group A subjects, in comparison to

group B subjects. This fact evidences a better clearance, both muscular and

hematological, of lactic acid. This lactic acid clearance, according to Brooks (8), is the

difference between the amount of lactic acid originated in the bloodstream (Ra) and that

eliminated from the bloodstream (Rd) in a time unit. When Ra is higher than Rd, then the

lactic acid level increases. The work associated to a sudden increase of lactate,

characterizes this condition as ‚lactate limit. The decrease of cap mean values

shown by group A subjects, could be attributed to an intracellular tampon effect

mechanism, due either to the MAP‚ constituent amino acids anphoteric characteristic,

or perhaps, to an increased lactate oxidation by the liver, heart or kidneys, through an

optimization of the enzimatic activities of the lactate-dehidrogenase (LDH) in those

organs. Future research is necessary to elucidate this matter.

k. A mean decrease of 44% higher of the differences between the prevailing and nonprevailing

leg in group A subjects, in comparison to group B subjects, during the PT60º,

PT300, TAE180, and TW240 tests. The improvement by decreasing the difference

between the prevailing and the non-prevailing muscles can be attributed to the subjects

insufficient protein intake prior to the study period. When body protein intake is

insufficient the body protein synthesis benefits the prevailing muscle, thus depriving the

non-prevailing one. This fact demonstrates that once the required body protein intake

was reassumed, by consuming MAP, the differences betweenl. We can conclude that the previous study results are significant, taking into consideration

that a. the subjects were well-trained and well-nourished athletes, with already optimized

physiological and anthropomorphic characteristics; b. the subjects only performed their

customary track and field running sport activity, which was not increased during the

study; and d. the study was carried-on only for a short period of 28 days.

m. We can conclude that the results of this study, confirming previous clinical studies,

results (1,2) have sufficiently demonstrated that MAP intake is highly beneficial to

optimize the anthropomorphic characteristics, the physical and physiological

performances, as well as, to optimize the lactic acid clearance. the subjects prevailing

and non-prevailing muscles were significantly decreased.

1. Luca Moretti. M. The Discovery of the Master Amino Acids Pattern. Annals of the Royal

Academy of Medicine of Spain. 1998:397-416.

2. Luca Moretti. M. Comparative Study of Subjects‚ Net Nitrogen Utilization while receiving

SON, a nutritional amino acid formula, or high biological value egg protein, or egg protein

amino acid formula. Advances in Therapy 9: 280-289, 1992.

3. Farrell, P.A., J.H. Wilmore, E.F. Coyle, J.E. Billings, and D.L. Costill. Plasma lactate

accumulation and distance running performance. Med. Sci. Sports 11:338-344, 1979.

4. Tanaka, K. and Y. Matsuura. Marathon performance, anaerobic threshold, and onset of

nlood lactate accumulation. J. Appl. Physiol. 57: 640-643,1984.

5. Davies G.J. A compendium of isokinetics in clinical usage. II Ed. La Crosse (WI): SeS

Publishers Ed, 1985.

6. Vender G., Rovelli E. Valori de riferimento dei principali paramitri de massima potenza

anaerobica misurati tramite ergometro isocinetico Cybex 340. Med Sport 1994; 47: 775-81.

7. Vender G., Rovelli E. Variazione delle prestazioni di massima potenza anaerobicain

funzione dell‚. Med Sport 1994; 47: 783-6.

8. Brooks G.A. Anaerobic threshold: review of the concept and direction for future research.

Med. Sci. Sports and Exercise. 17: 22-31, 1985.

Share

See More in the Store

sports performance supplements
Sports Performance and Training Blog is proudly powered by WordPress | Entries (RSS) and Comments (RSS).
© 2008 Protocol Supplements